Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

Returns on capital

Iovance Biotherapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-56.0%

avg -52.0%

ROIC

-50.9%

avg -48.9%

ROA

-42.8%

avg -43.4%

Analysis

ROA is currently the strongest return metric at -42.8% versus its period average of -43.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Frederick G. Vogt

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & DirectorUSD 1.13M520<0.01%

Raj K. Puri

Chief Regulatory OfficerUSD 867.16K7058.60K0.02%

Daniel G. Kirby

Chief Commercial OfficerUSD 804.03K54——

Igor Bilinsky

Chief Operating OfficerUSD 738.37K5346.88K0.01%

Corleen Roche

Chief Financial OfficerUSD 494.15K60——

Brian Gastman

Executive Vice President of Translational Medicine & Research————

Howard Johnson

Chief Business Officer—66——

Kevin Smyth

Executive Vice President of Quality————

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications————

Tracy Winton

Executive Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+40.9% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Forward estimates point to Revenue at +40.9% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Iovance Biotherapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IOVA's management, answered from reported figures.

Who manages IOVA?

Iovance Biotherapeutics, Inc. (IOVA) lists 10 active executives. The top listed executive is Brian Gastman, Executive Vice President of Translational Medicine & Research.

Are IOVA insiders buying or selling?

Recent insider activity shows net selling of $1.08M.